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ABSTRACT
Objectives. Behçet’s disease has been 
historically classiﬁed as a Th1 disease. 
The recently described IL-17/IL-23 
pathway seems to play an important 
role in many inﬂammatory diseases and 
in the intestinal abnormalities of AS 
and CD. The aim of the present study 
was to evaluate the IL-17/IL-23 axis in 
parallel with Th1 and IL-27 response 
in the intestine of patients with BD and 
gastrointestinal abnormalities. 
Methods. Quantitative TaqMan re-
verse transcriptase-polymerase chain 
reaction (RT-PCR) was utilised for all 
determinations on ileal biopsy speci-
mens obtained from BD, AS and CD 
patients. The serum levels of Th1 and 
Th17 cytokines were evaluated by en-
zyme-linked immunosorbent assay.
Results. A Th1 but not a Th17 response 
is present in the gastrointestinal in-
volvement of Behçet’s disease. 
Conclusions. Although BD shares 
clinical manifestations with both CD 
and AS, the immunologic abnormalities 
seen in the intestine are quite different, 
indicating that other immune mecha-
nisms should be taken into account.
Introduction
Behçet’s disease (BD) is a rare vascu-
litis characterised by recurrent oral and 
genital ulcers, eye lesions, skin lesions 
and positive pathergy test. Oral ulcers, 
erythema nodosum, uveitis and arthri-
tis are common manifestations of BD 
together with intestinal inﬂammation 
but also of ankylosing spondylitis (AS) 
and Crohn’s disease (CD). 
We have recently produced evidence 
that AS and CD share some clinical and 
immunological similarities at gastroin-
testinal level (1). 
Activation of T cells and monocytes/
macrophages is regarded as an impor-
tant factor in the pathogenesis of BD 
as well as AS and CD. Historically BD 
has been considered to be a typical Th1 
disease, characterised by increased lev-
els of Th1 cytokines such as IFN-γ, IL-
2 and TNF-α (2, 3). 
The IL-17/IL-23 pathway seems to 
play an important role in many in-
ﬂammatory diseases (4) and in the in-
testinal abnormalities of AS and CD 
(1). Increased IL-17 levels have been 
found in the sera of BD patients (5), it 
is not yet clear, however, whether the 
IL-17/IL-23 pathway is involved in the 
pathogenesis of the intestinal BD. Data 
available, in fact, on cytokine produc-
tion in the gut of BD patients are lim-
ited and indicate a small impairment of 
Th1 cytokines (6). 
The aim of the present study was to 
evaluate the IL-17/IL-23 axis in paral-
lel with Th1 response in the intestine of 
patients with BD and gastrointestinal 
abnormalities.   
Patients and methods
Intestinal biopsy specimens were ob-
tained, after informed consent, from 
11 patients (7 males and 4 females, age 
range 25–58 years) with BD and intes-
tinal complaints. Two adjacent mucos-
al biopsy samples from the ileum were 
obtained from each subject, independ-
ently of the presence of macroscopic 
involvement. All patients fulﬁlled the 
international criteria for disease classi-
ﬁcation and were considered to have an 
active disease (7). Ileal specimens from 
10 healthy subjects, 8 AS and 7 CD pa-
tients who underwent ileocolonscopy 
for routine clinical evaluation were 
also included as healthy and disease 
controls, respectively. The AS group 
consisted of 5 men and 3 women with 
a median age of 41 years (range 38–65 
years) who were diagnosed as having 
AS according to the modiﬁed New 
York criteria (8). Disease activity was 
evaluated using the Bath AS Disease 
Activity Index (BASDAI) (9), with a 
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BASDAI score of >4 indicating active 
disease. All patients were HLA–B27 
positive. At the time mucosal biopsy 
specimens were obtained, the mean ± 
SD BASDAI score was 6.7±3.4. The 
CD group consisted of 5 men and 2 
women with a median age of 50 years 
(range 48–60 years). The diagnosis of 
CD was made according to clinical pa-
rameters and ﬁndings of radiographic, 
endoscopic, and histopathologic analy-
ses. Disease activity was evaluated us-
ing the CD Activity Index (10), with a 
score >150 indicating active disease, 
and endoscopic and histopathologic 
data. At the time of sample collection, 
the mean ± SD CD Activity Index score 
was 253±51.5, and none of the patients 
had received steroids and/or cytotoxic 
drugs, immunosuppressive agents, or 
antibiotics. The control group (NHS) 
consisted of 6 men and 4 women with 
a median age of 45 years (range 41–58 
years) who were undergoing ileo-
colonoscopy for diagnostic purposes. 
The study was approved by the ethics 
committee and the institutional review 
board of the University of Palermo.
The quantitative TaqMan reverse tras-
criptase-polymerase chain reaction 
(RT-PCR) was utilised for all deter-
minations as extensively described in 
reference 1. Total RNA was extracted 
using the Qiagen RNeasy Mini kit 
(Qiagen, Chatsworth, CA), with on-
column DNase I digestion. A total of 1 
μg of RNA was reverse-transcribed to 
complementary DNA (cDNA) using a 
ThermoScript First-Strand cDNA Syn-
thesis kit (Invitrogen, Carlsbad, CA). 
Samples were run in triplicate at 20 ng 
of cDNA per well and detected using 
an ABI Prism 7900HT instrument. Re-
sults were analysed using ABI Prism 
7900HT Sequence Detection System 
version 2.1 software. Relative quan-
tiﬁcation was assessed using the Ct 
method. 
IL-12, IL-17, IFN-γ, TNF-α serum 
levels were analysed with Human 
Autoimmune Response Multi-Ana-
lyte ELISArray kits (SABiosciences 
Corp, Frederick, Md) according to the 
manufacturer’s instructions. IL-23 and 
IL-27 serum levels were evaluated us-
ing commercially available kits (R&D 
Systems, Minneapolis, MN).
Statistics
Results are expressed as mean ± SD. 
Statistical analysis of quantitative 
variables was performed using the 
Kruskal-Wallis nonparametric test, 
with Dunn’s post test when analysing 
more than 2 groups and the Mann-
Whitney U-test when analysing 2 
groups. P-values less than 0.05 were 
considered signiﬁcant.
Results
Six patients complain abdominal pain, 
4 diarrhoea and one both. At morphol-
Fig. 1. IL-23, IL-17, IL-1β, IL-27, INF-γ, TNF-
α, IL-12, STAT-3 and suppressor cytokine sig-
nalling 3 (SOCS-3) – related gene expression 
assessed by TaqMan real-time polymerase chain 
reaction in ileal biopsy specimens obtained from 
patients with Behçet’s disease (BD), ankylosing 
spondylitis (AS), Crohn’s disease (CD), and nor-
mal controls (HC).
Bars show the mean and SD.
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ogy patients showed chronic non-spe-
ciﬁc inﬂammatory abnormalities and 
in some cases venule vasculitis and 
apthous ulcers. Patients were untreated 
(n=3) or treated with colchicine (n=4) 
low dose prednisone (n=2) or both 
(n=2). None was under immunosup-
pressants. All CD patients had an ac-
tive disease. Of the 8 patients with ac-
tive AS who underwent colonoscopy 
(mean BASDAI score 6.7), evidence 
of subclinical intestinal inﬂammation 
was observed in 5 (one with acute in-
ﬂammation and 4 with chronic inﬂam-
mation). Results are shown in Figure 1. 
In contrast with results obtained in AS 
and CD patients, normal levels of IL-
23 mRNA were found in BD. STAT-3, 
which mediates IL-23 signalling upon 
IL-23 receptor ligation, and IL-17A 
mRNA were also normal. Samples 
from BD patients displayed SOCS-3 
over expression at levels comparable 
to those observed in CD but not in 
AS patients. Levels of TNF-α, IFN-γ, 
IL-12p35 mRNA in BD specimens 
were signiﬁcantly higher than those of 
healthy controls and AS and compara-
ble to those found in CD. Interestingly 
IL-27, a Th1 cytokine which inhibits 
de novo Th17 development from naive 
T cells (11) was found to be markedly 
up-regulated at levels similar to those 
found in CD. 
Analysis of serum cytokines showed 
increased concentrations of IL-12, 
TNF-α and IFN-γ in BD patients when 
compared to NHS (Fig. 2). A trend to-
ward an increase in IL-17, IL-23 and 
IL-27, (although not statistically sig-
niﬁcant) was observed in BD patients 
versus NHS. 
Discussion
The presence of a shared clinical be-
haviour between BD, AS and CD is 
suggested by evidence of similar ar-
thropathy, intestinal inﬂammation and 
muco-cutaneous abnormalities in pa-
tients with either disease. 
Based on recent ﬁndings, it is becom-
ing increasingly clear that IL-23 ex-
erts an essential pathogenetic role in 
promoting autoimmunity and chronic 
inﬂammation in several models of au-
toimmune diseases, such as experi-
mental inﬂammatory arthritis (12) and 
experimental colitis (13). In this and 
our previous study (1) we have demon-
strated a strong and signiﬁcant up-reg-
ulation of IL-23p19 transcripts in the 
terminal ileum of patients with AS and 
patients with CD. Unlikely CD and AS, 
in BD patients IL-23 was not up-regu-
lated and there was no involvement of 
the IL-17/IL-23 pathway.  On the other 
hand, intestinal BD seems to be char-
acterised by a Th1 response. Levels of 
TNF-α, IFN-γ, IL-12p35 mRNA were, 
in fact, signiﬁcantly higher than those 
of healthy controls and AS and compa-
rable to those found in CD. IL-27 was 
found also markedly up-regulated and 
may account for the limited Th-17 cell 
pool in the BD intestine (11). Analy-
sis of serum cytokines concentration 
by ELISArrays showed a marked and 
signiﬁcant increase of Th1, but not 
Th17 cytokines in BD patients when 
compared to NHS. The Th1 prevalent 
response in BD could be related to a 
defective regulatory T cell response as 
suggested by a recent study showing 
that TGF-beta1 and IL-10 gene poly-
morphism may affect host susceptibil-
ity to BD (14).
At present we do not know whether 
mRNA levels found in our patients are 
paralleled by their corresponding pro-
tein levels. However, the BD popula-
tion in this study was not large enough 
to consent deﬁnite conclusions. Some 
considerations, however, may be done. 
In particular, although BD shares clini-
cal manifestations with both CD and AS, 
the immunologic abnormalities seen in 
the intestine are quite different indicat-
ing that other immune mechanisms, 
possibly involving gamma/delta T cells 
(15), should be taken into account.
Fig. 2. IL-12 (A), IFN-γ (B), TNF-α (C), IL-17 (D) IL-23 (E), and IL-27 (F) were measured in serum 
samples from patients with Behçet’s disease (BD) and healthy controls (HC) by ELISArrays. A-D data 
are presented as absorbance values at 450 nm. IL-23 and IL-27 levels are expressed as pg/ml.
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